All Articles

Ottawa's first national eye care strategy isn't just about health. It's a calculated investment in economic resilience and systemic stability for an aging nation.

The Stoneport Commodity ETF is liquidating after just seven months. Its story reveals the harsh, unsentimental system governing the competitive ETF market.

Digital health firm Osara Health is targeting the 'Cancer Care Cliff,' backing its new survivorship program with a validated 25:1 ROI and proven health outcomes.

The 10-year extension for the Las Vegas Grand Prix is more than a race deal; it's a high-stakes maneuver cementing F1's US strategy amid local growing pains.

A new, ultra-premium bourbon honors Secretariat's greatest win. But this is more than a drink; it's a case study in legacy, luxury, and market disruption.

Zealand Pharma's petrelintide shows double-digit weight loss with remarkably few side effects, positioning it to challenge GLP-1 giants in the $100B market.

Fifteen high schoolers, mentored by racing icons, turned a Harley Nightster into a track-ready beast, proving the power of hands-on technical education.

DBV Technologies heads to a key investor conference with its VIASKIN patch for peanut allergies. Can its science and strategy convince Wall Street?

The Ontario Science Centre's event with astronaut Jeremy Hansen is more than a celebration; it's a strategic play for relevance and a national talent drive.

A small biotech is about to reveal data on a novel drug that could change autoimmune care. Will its bold scientific strategy pay off for patients and investors?

A Toronto meeting signals a new era for Canada-Grenada ties. It's a calculated move into geothermal energy, regional security, and high-value trade.

The federal government hails its new AI strategy as 'pro-worker,' but a major public service union warns it lacks crucial safeguards, risking jobs and services.

Ottawa unveils a multi-billion dollar plan to transform Canada from an AI research hub into an economic leader, focusing on adoption, sovereignty, and ethics.

Ottawa's new "AI for All" plan promises to revolutionize healthcare, but can its 'ironclad protections' keep pace with the technology it's unleashing?

As whistleblower law gains formal recognition, a top-tier ranking for Pugsley Wood LLP signals a new era of corporate accountability and strategic risk.

As Pacira BioSciences fends off an activist investor, a high-stakes proxy fight pits long-term R&D against demands for short-term returns.

Wilson Elser’s 2026 Chambers rankings reveal more than legal wins; they map a strategy of mastering niche markets from cannabis law to NTSB disasters.

With record profits and a booming backlog, M-tron Industries is pitching its critical role in national security to top investors. Here's why they're listening.

A new alliance between General Fluidics and Invetech seeks to move lab testing from centralized facilities to the clinic, promising faster, more accessible care.

As AI and crypto converge, a new project bets its future not on speculation, but on tangible utility and verifiable security. We deconstruct the model.